Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)

AstraZeneca197 enrolled

Overview

This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months

Study Type

OBSERVATIONAL

Enrollment

197

Conditions

Prostatic Cancer

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Prostate cancer patient requiring androgen-ablation treatment: LHRH analogs, surgical castration, antiandrogen treatment * Provision of informed consent prior to conducting any study-related procedure Exclusion Criteria: * Patient involved in a Clinical Trial

Locations (33)

Research Site

Albacete, Albacete, Spain

Outcomes

Primary Outcomes

Metabolic syndrome

Time frame: 3 months

Metabolic syndrome

Time frame: 6 months

Metabolic syndrome

Time frame: 12 months

Diabetes

Time frame: 3 months

Diabetes

Time frame: 6 months

Diabetes

Time frame: 12 months

Secondary Outcomes

Fracture Risk Assessment Tool (FRAx) assessment

Time frame: 0 and 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.